Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

The venetoclax combined with metronomic low-dose decitabine and interferon for preventing post-transplant relapse in high-risk MDS and AML patients

View Full Paper
Ask AI
Bookmark
Share

Authors

XHXiaobing Huang

Discussion

Loading...

Member takes

Overview

Single-arm retrospective cohort study demonstrates improved overall survival in high-risk MDS/AML patients after allo-HSCT, indicating potential of venetoclax and interferon treatment.

Key Points

  • Significantly reduces relapse rates post-allo-HSCT in high-risk MDS/AML patients, enhancing overall survival.
  • Reported a 12-month overall survival rate of 92.4% and event-free survival rate of 88.2%, indicating efficacy.
  • Single-center retrospective cohort study included 33 patients treated with venetoclax, metronomic decitabine, and interferon.
  • Highlights a manageable safety profile with common adverse events including neutropenia and infections.

Cite This Study

Xiaobing Huang (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2edhttps://doi.org/10.1182/blood-2025-7793
View Full Paper
Ask AI
Bookmark
Share